18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
Ozempic, Mounjaro and retatrutide compared

Ozempic vs Mounjaro vs retatrutide: what is the difference?

Ozempic, Wegovy, Mounjaro and retatrutide come up in almost every conversation about weight loss, and the names cause a lot of confusion. Behind the brand names there are only three molecules: semaglutide, tirzepatide and retatrutide. This guide explains which brand is which, how they differ, what the trials showed, and how the branded medicines relate to the research compounds we supply.

Ozempic vs Mounjaro vs retatrutide in 60 seconds

  • Ozempic and Wegovy are brand names for semaglutide (Novo Nordisk). Ozempic is for type 2 diabetes, Wegovy is a higher dose for weight management.
  • Mounjaro is the brand name for tirzepatide (Eli Lilly). In the US it is also sold for weight management as Zepbound.
  • Retatrutide is Eli Lilly’s next compound. It is still in trials and has no brand name yet.
  • In the trials, average weight loss went up with each step: semaglutide, then tirzepatide, then retatrutide.
  • The trials were run separately, so this is a rough guide and not a head-to-head result.

Brand names and molecules

Brand nameMoleculeMade byActs on
OzempicSemaglutideNovo NordiskGLP-1
WegovySemaglutide (higher dose)Novo NordiskGLP-1
RybelsusSemaglutide (tablet)Novo NordiskGLP-1
MounjaroTirzepatideEli LillyGLP-1 and GIP
Zepbound (US)TirzepatideEli LillyGLP-1 and GIP
None yetRetatrutideEli LillyGLP-1, GIP and glucagon

How they work: one, two or three hormone signals

All three copy gut hormones that tell the brain you are full and help the body handle sugar. The difference is how many hormone receptors each one acts on.

One signal, then two, then three

  1. Semaglutide (Ozempic, Wegovy): GLP-1. Slows stomach emptying and turns down appetite.
  2. Tirzepatide (Mounjaro): GLP-1 and GIP. The second hormone appears to add to the effect on weight and blood sugar.
  3. Retatrutide: GLP-1, GIP and glucagon. Glucagon raises energy use, which is the thinking behind its larger results.

Our retatrutide vs tirzepatide vs semaglutide guide goes deeper on the receptors.

Weight loss in the trials

Semaglutide (Wegovy dose)Tirzepatide (Mounjaro)Retatrutide
Main trialSTEP 1SURMOUNT-1Phase 2
Average weight loss, top doseAbout 15%About 21%About 24%
Over68 weeks72 weeks48 weeks
How oftenOnce a weekOnce a weekOnce a week
StatusApproved medicineApproved medicineStill in trials

Worth sitting with. A bigger average does not mean a better result for any one person. Averages hide a wide spread, and side effects tend to rise with the dose.

Side effects

The side effects are similar across all three, because they share the GLP-1 action: nausea, diarrhoea, constipation and vomiting, mostly while the dose is being increased. Starting low and going up slowly is the main way to keep them down. Rare but serious risks include pancreatitis and gallbladder problems. Our peptide side effects guide covers what to watch for.

Branded medicine or research compound?

Registered medicines

  • Ozempic, Wegovy and Mounjaro
  • Prescribed by a doctor
  • Dispensed by a pharmacy
  • Come with medical supervision

Research compounds we supply

  • Semaglutide, tirzepatide and retatrutide
  • The same molecules, made by other manufacturers
  • Sold for research use only
  • Not Ozempic, Wegovy or Mounjaro, and no doctor’s supervision

If you are considering a prescription medicine, speak to your doctor. See also peptides at Dis-Chem or Clicks.

Which one fits your research?

  • Semaglutide: the most studied, the longest track record, and usually the lowest outlay.
  • Tirzepatide: more weight loss than semaglutide in the trials, with a large body of research.
  • Retatrutide: the largest results so far, but the newest and least studied.

Live prices per milligram for every option are on our semaglutide, tirzepatide and retatrutide pages.

Semaglutide, tirzepatide and retatrutide we stock

Frequently asked questions

Is semaglutide the same as Ozempic?

Ozempic is a branded medicine whose active ingredient is semaglutide. Wegovy is a higher-dose semaglutide brand for weight management. The research semaglutide we supply is the same molecule, but it is not Ozempic or Wegovy, which are registered medicines.

Is tirzepatide the same as Mounjaro?

Mounjaro is the branded medicine whose active ingredient is tirzepatide. Research tirzepatide is the same molecule but is not the registered medicine.

Which causes more weight loss, Ozempic or Mounjaro?

In the large trials, tirzepatide (Mounjaro) produced more weight loss than semaglutide (Ozempic and Wegovy): about 21% at the top dose over 72 weeks, against about 15% over 68 weeks.

Is retatrutide stronger than Mounjaro?

In its trials so far, retatrutide produced the largest average weight loss of the three, but it is still being studied and is not approved anywhere. It has not been compared head to head with tirzepatide in a published trial.

Are Ozempic and Mounjaro peptides?

Yes. Semaglutide, tirzepatide and retatrutide are all peptides, which is why they are injected rather than swallowed (apart from the oral semaglutide tablet).

Is retatrutide stronger than Ozempic?

In the trials so far, retatrutide produced more weight loss on average: about 24% at the top dose in its phase 2 trial over 48 weeks, against about 15% for semaglutide at the Wegovy dose over 68 weeks. These were separate trials in different people over different lengths of time, so this is not a head-to-head comparison. Retatrutide acts on three hormone receptors where semaglutide acts on one, and it is not approved anywhere. Ozempic is a registered medicine.

What is the difference between retatrutide and Mounjaro?

Mounjaro is tirzepatide, which acts on two receptors (GLP-1 and GIP). Retatrutide adds a third, glucagon. Its phase 2 trial averaged about 24% weight loss at the top dose over 48 weeks, against about 21% over 72 weeks for tirzepatide in SURMOUNT-1. In May 2026 Eli Lilly reported 28.3% at 80 weeks on the highest dose in the first phase 3 trial (TRIUMPH-1). No head-to-head trial has been published, and retatrutide is not approved anywhere.

Sources

  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2206038
  • Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023. doi.org/10.1056/NEJMoa2301972

Everything we sell is supplied for research use only and is not a registered medicine. Nothing here is medical advice.

Related reading: slimming injections in South Africa.

More on this: GLP-1s in South Africa and weight-loss injections in South Africa.